(Press-News.org) TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.
C-Path’s demonstrated expertise will be leveraged to ensure success, specifically its track record in generating tangible solutions that have accelerated drug development in rare and pediatric indications, utilizing the power of C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) to integrate multiple patient-level data sources. This collaborative task force will provide a neutral environment for industry, regulatory agencies, academia, and the patient community to collaborate and actively contribute to advancing solutions aimed at facilitating therapeutic developments for these communities.
“Uniting stakeholders through a neutral convener such as C-Path will enable our community to collaborate better, share data, and accelerate the development of much-needed treatments,” explained Sophia Zilber, Cure MITO Foundation board member. “We are grateful to C-Path for their partnership, and collaboration in assembling this initiative, and look forward to the next steps and achievements as this task force takes shape.”
Mitochondrial and inherited metabolic diseases can affect one part of the body or many parts, and these effects can be mild or very serious. Symptoms range from fatigue and exercise intolerance to poor growth, muscle weakness, developmental delays, vision/hearing loss, stroke, seizures, heart failure, and kidney failure, among others.
“Through our ongoing experience within different consortia at C-Path, we now hope to accelerate the discovery and development of treatments for patients with mitochondrial diseases. We look forward to our work with C-Path and other members of this task force,” says Dima Martini-Drew, M.D., Astellas Medical Affairs Mitochondrial and Rare Disease.
“Finding pathways to effective treatments from the mitochondrial research communities requires unique collaborations across institutions, industry, and researchers,” says Gordon Freedman, the organizer of Mitochondria World, a global information source for the emerging field of mitochondrial biology. “C-Path brings the right tools and methods to speed the process for much-needed therapies.”
“C-Path is uniquely positioned to lead this new task force,” explained Amanda Klein, Pharm.D., C-Path’s Executive Director of the Transplant Therapeutics Consortium and lead for this task force. “We thank the communities for recognizing the importance of collaborative projects. We look forward to leveraging our core competencies to provide strategic and tactical guidance, engage relevant stakeholders, and bring diverse expertise to generate the solutions to help patients and their families.”
The Institute’s core competencies, which include expertise in data management standards, biomarkers, modeling and analytics, regulatory science, and clinical outcome assessments, help de-risk decision-making in drug development and regulatory review of novel therapeutics.
To learn more and inquire about joining C-Path’s mitochondrial and inherited metabolic diseases task force, contact rdca-dapadmin@c-path.org.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
About RDCA-DAP
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), a joint initiative by C-Path and NORD with support from FDA, offers a unique platform promoting cooperation among various stakeholders, including academic institutions, industry leaders, healthcare organizations, and patient advocacy groups. It accelerates the development of treatments for rare diseases through data sharing, analysis, and collaboration. For more information, visit c-path.org/rdca-dap.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at astellas.com/en.
About The Champ Foundation
The Champ Foundation is a 501(c)(3) nonprofit organization that was founded in 2015 with a mission to find treatment and a cure for Pearson syndrome and single large-scale mtDNA deletion syndromes (SLSMDS). The Champ Foundation has funded over $2 million in research grants and activities, hosted international family-friendly research conferences, funded and launched a multi-site Natural History Study, and spearheaded the Champ Foundation Registry, the largest repository of data for individuals with SLSMDS. In 2020, The Champ Foundation was selected as part of the Rare As One cohort, and received a multi-year grant from the Chan Zuckerberg Initiative to establish a SLSMDS research network. For more information, please visit thechampfoundation.org or follow us on Facebook, Instagram, or Twitter.
About Cure LBSL
Cure LBSL, formerly known as “A Cure For Ellie”, is an international non-profit foundation supporting patients and families affected by LBSL (Leukoencephalopathy with Brain Stem and Spinal Cord Involvement and Lactate Elevation). LBSL is an ultra-rare neurodegenerative disorder, also known as mitochondrial aspartyl-tRNA synthetase deficiency. The foundation mission is to bring awareness, support, and hope to patients and families, and to fund and accelerate research into potential treatments and cures. curelbsl.org
About Cure Mito Foundation
Cure Mito Foundation is a parent-led 501(c)(3) nonprofit organization that was founded in 2018 by a group of families determined to fight for their children’s lives. Cure Mito’s mission is to unite the global Leigh syndrome community to accelerate patient-centered research, treatments, and cures. Cure Mito has an international reach with patients from over 35 countries, currently a part of the Leigh syndrome global patient registry that Cure Mito has developed. Cure Mito funds promising research and strengthens and unites the community through such initiatives as its annual Leigh syndrome symposium and informational website AboutLeighSyndrome.com. Cure Mito is a member of Defense Health Research Consortium, COMBINEDBrain, Global Genes Foundation Alliance, Everylife Foundation Community Congress, and Indo US Rare Organization for Rare Diseases. Cure Mito has been rated as a Top-Rated Nonprofit by @GreatNonprofits. For more information, please visit: curemito.org or follow Cure Mito on LinkedIn | Twitter | Facebook | Instagram.
About Hope for PDCD
Hope for PDCD was founded by PDCD parents in 2022 with an urgent mission: to cure a fatal childhood disease known as Pyruvate Dehydrogenase Complex Deficiency. All financial gifts are invested wisely: 100% of every dollar donated goes to research and advocacy efforts for PDCD. Hope for PDCD has quickly grown into a collective of volunteer parent board members, scientific advisors, and industry partners. Hope for PDCD aims to fund a multi-million dollar research project into new therapeutics for PDHA1 mutations, newborn screening, standards of care, the first ever PDCD-specific patient registry, biomarkers and clinical endpoints. Hope for PDCD serves the PDCD patient community by offering a state-by-state clinician directory, free genetic testing, resources on the ketogenic diet and more. Find out more at hopeforpdcd.org.
About Midwestern University
Midwestern University is a private, not-for-profit graduate and postgraduate educational institution specializing in the health sciences with 12 colleges located on two campuses. The Illinois campus, located on a 105-acre site in Downers Grove, is home to nearly 3,000 students and the Chicago College of Osteopathic Medicine; the College of Pharmacy, Downers Grove; the College of Health Sciences, Downers Grove; the College of Dental Medicine-Illinois; the Chicago College of Optometry; and the College of Graduate Studies, Downers Grove. The Arizona campus, located on a 156-acre site in Glendale, is home to over 3,900 students and the Arizona College of Osteopathic Medicine; the College of Pharmacy, Glendale; the College of Health Sciences, Glendale; the College of Dental Medicine-Arizona; the Arizona College of Optometry; the College of Veterinary Medicine; the College of Graduate Studies, Glendale; and the Arizona College of Podiatric Medicine. The University is accredited by The Higher Learning Commission, a Commission of the North Central Association of Colleges and Schools. For more information, visit midwestern.edu or call 623/572-3215.
About MitochondriaWorld
MitochondriaWorld is a nonprofit mitochondrial research and advocacy organization that brings together academic investigators, biopharmaceutical companies, clinical groups, and patients. It serves as a nexus for mitochondria specialists and patient groups to build community, drive research, and coordinate large-scale collaborations. The goal of MitochondriaWorld is to breakdown research silos and disseminate scientific insights from global mitochondrial research and clinical communities to accelerate breakthroughs in basic science and the development of metabolic therapies. Join our mission at MitoWorld.org.
END
C-path to lead new task force aimed at accelerating drug development for mitochondrial and inherited metabolic diseases
2024-01-11
ELSE PRESS RELEASES FROM THIS DATE:
Molecularly designing polymer networks to control sound damping
2024-01-11
The world is filled with a myriad of sounds and vibrations—the gentle tones of a piano drifting down the hall, the relaxing purr of a cat laying on your chest, the annoying hum of the office lights. Imagine being able to selectively tune out noises of a certain frequency. Researchers at the University of Illinois Urbana-Champaign have synthesized polymer networks with two distinct architectures and crosslink points capable of dynamically exchanging polymer strands to understand how the network connectivity and bond exchange mechanisms govern the overall damping behavior of the network. The incorporation of dynamic bonds into the polymer network demonstrates ...
Year-end survey spotlights food safety, age-related consumer behavior, out-of-stock trends
2024-01-11
WEST LAFAYETTE, Ind. — Building off the previous month’s survey, the December 2023 Consumer Food Insights Report digs deeper into the relationships between food-date labels and the decision to discard food. The report also explores generational differences in food behaviors and reviews 2023 trends for out-of-stock items and common foods that people reported limiting in their diets over the year.
The survey-based report out of Purdue University’s Center for Food Demand Analysis and Sustainability assesses food spending, consumer satisfaction and values, support ...
Mike Norvell named 2023 Paul “Bear” Bryant Coach of the Year
2024-01-11
HOUSTON, January 10, 2024 – Mike Norvell, head coach at Florida State University, was named college football Coach of the Year at the American Heart Association’s Paul “Bear” Bryant Awards, presented by Marathon Oil. The 38th annual awards program benefits the American Heart Association, the world’s leading voluntary health organization devoted to a world of longer, healthier lives for all.
In his fourth season as the head coach at Florida State, Norvell led the Seminoles to a 13-1 overall record and an 8-0 mark in the Atlantic Coast Conference (ACC). Norvell was previously honored as the ACC Coach of the Year and was ...
Study reveals wastewater surveillance is key tool in keeping schools open during public health emergencies
2024-01-11
Wastewater surveillance is a potent tool in understanding COVID-19 transmission within school settings, according to a ground-breaking study led by epidemiologist David Larsen from Syracuse University.
The research team’s work that was published recently in PLOS Global Public Health establishes the pivotal role of wastewater analysis in managing the public health response to COVID-19 at schools.
The study focused on a middle and high school campus in Jefferson County, New York, serving 600 students and compared results from wastewater surveillance to COVID-19 case trends. The surveillance ...
Loss of executive function may signal onset of neurodegenerative condition FXTAS
2024-01-11
New UC Davis research shows that men with an FMR1 premutation who experienced reduced executive function were at higher likelihood of developing fragile X-associated tremor/ataxia syndrome (FXTAS).
FXTAS is a progressive genetic condition that causes movement issues and cognitive decline. These findings, published in the journal Movement Disorders, could help clinicians determine which premutation carriers will eventually develop FXTAS.
“There's converging evidence that the premutation is affecting certain circuits in the brain ...
The first assessment of toxic heavy metal pollution in the Southern Hemisphere over the last 2,000 years
2024-01-11
Human activity, from burning fossil fuels and fireplaces to the contaminated dust produced by mining, alters Earth’s atmosphere in countless ways. Records of these impacts over time are preserved in everlasting polar ice that serves as a sort of time capsule, allowing scientists and historians to link Earth’s history with that of human societies. In a new study, ice cores from Antartica show that lead and other toxic heavy metals linked to mining activities polluted the Southern Hemisphere as early as the 13th century.
“Seeing evidence that early Andean ...
Bulky additives could make cheaper solar cells last longer
2024-01-11
Images
An insight into preventing perovskite semiconductors from degrading quickly, discovered at the University of Michigan, could help enable solar cells estimated to be two to four times cheaper than today's thin-film solar panels.
Perovskites may also be combined with the silicon-based semiconductors that are prevalent in today's solar panels to create "tandem" solar cells that could surpass the maximum theoretical efficiency of silicon solar cells.
"Silicon solar cells are great because they are very efficient and can last for a very long time, but the high efficiency comes with a high cost," ...
A global study reveals pathways to save threatened sharks, despite rising mortality trends
2024-01-11
Sharks have persisted as powerful ocean predators for more than 400 million years. They survived five mass extinctions, diversifying into an amazing variety of forms and lifestyles. But this ancient lineage is now among the world's most threatened species groups due to overexploitation in poorly regulated fisheries and the proliferation of wasteful finning practices.
Governments around the world have introduced a host of regulations aimed at reducing shark catch and finning, the latter of which typically sees valuable shark fins retained for sale while carcasses are discarded at sea. But until ...
Discovered in the Upper Amazon: 2500-year-old landscape providing evidence for early urbanism in the region
2024-01-11
A dense system of pre-Hispanic urban centers, characterized by constructed platforms and plazas and connected by large, straight roads, has been discovered in the upper Amazon, according to a new study. The research, based on more than 20 years of interdisciplinary research, suggests that this original 2500-year-old society constitutes the earliest and largest low-density agrarian urbanism documented in the Amazon thus far. Such extensive early development in the Upper Amazon resembles similar Maya urban systems in Central America. ...
Machine learning clinical prediction models fail to generalize across trial data
2024-01-11
Clinical prediction models for schizophrenia treatment outcomes that work well within the trials from which they were developed fail to generalize to future trials, according to a new study. “The findings not only highlight the necessity for more stringent methodological standards for machine learning approaches but also require reexamination of the practical challenges that precision medicine is facing,” writes Frederike Petzschner in a related Perspective. Despite receiving the same treatments for the same afflictions, some patients get better while others show no improvement. Precision medicine approaches seek to address this problem by providing tailored treatments for individual ...